-
1
-
-
0035881074
-
Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma
-
Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19:3635-3648.
-
(2001)
J Clin Oncol
, vol.19
, pp. 3635-3648
-
-
Balch, C.M.1
Buzaid, A.C.2
Soong, S.J.3
-
2
-
-
0033989205
-
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma
-
Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000;18:158-166.
-
(2000)
J Clin Oncol
, vol.18
, pp. 158-166
-
-
Middleton, M.R.1
Grob, J.J.2
Aaronson, N.3
-
3
-
-
0032858487
-
Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma
-
Chapman PB, Einhorn LH, Meyers ML, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol. 1999;17:2745-2751.
-
(1999)
J Clin Oncol
, vol.17
, pp. 2745-2751
-
-
Chapman, P.B.1
Einhorn, L.H.2
Meyers, M.L.3
-
4
-
-
0031805725
-
Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: An Eastern Cooperative Oncology Group study
-
Falkson CI, Ibrahim J, Kirkwood JM, Coates AS, Atkins MB, Blum RH. Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol. 1998;16:1743-1751.
-
(1998)
J Clin Oncol
, vol.16
, pp. 1743-1751
-
-
Falkson, C.I.1
Ibrahim, J.2
Kirkwood, J.M.3
Coates, A.S.4
Atkins, M.B.5
Blum, R.H.6
-
5
-
-
0033024863
-
High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993
-
Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17:2105-2116.
-
(1999)
J Clin Oncol
, vol.17
, pp. 2105-2116
-
-
Atkins, M.B.1
Lotze, M.T.2
Dutcher, J.P.3
-
6
-
-
0030030347
-
Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684
-
Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996;14:7-17.
-
(1996)
J Clin Oncol
, vol.14
, pp. 7-17
-
-
Kirkwood, J.M.1
Strawderman, M.H.2
Ernstoff, M.S.3
Smith, T.J.4
Borden, E.C.5
Blum, R.H.6
-
7
-
-
0034088027
-
High- and low-dose interferon alfa-2b in high-risk melanoma: First analysis of intergroup trial E1690/S9111/C9190
-
Kirkwood JM, Ibrahim JG, Sondak VK, et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol. 2000;18:2444-2458.
-
(2000)
J Clin Oncol
, vol.18
, pp. 2444-2458
-
-
Kirkwood, J.M.1
Ibrahim, J.G.2
Sondak, V.K.3
-
8
-
-
0035339880
-
High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of intergroup trial E1694/S9512/C509801
-
Kirkwood JM, Ibrahim JG, Sosman JA, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol. 2001;19:2370-2380.
-
(2001)
J Clin Oncol
, vol.19
, pp. 2370-2380
-
-
Kirkwood, J.M.1
Ibrahim, J.G.2
Sosman, J.A.3
-
9
-
-
0034043168
-
A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alpha-2B in patients with metastatic melanoma
-
McDermott DF, Mier JW, Lawrence DP, et al. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alpha-2B in patients with metastatic melanoma. Clin Cancer Res. 2000;6:2201-2208.
-
(2000)
Clin Cancer Res
, vol.6
, pp. 2201-2208
-
-
McDermott, D.F.1
Mier, J.W.2
Lawrence, D.P.3
-
10
-
-
0037089629
-
Sequential biochemotherapy versus chemotherapy for metastatic melanoma: Results from a phase III randomized trial
-
Eton O, Legha SS, Bedikian AY, et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol. 2002;20:2045-2052.
-
(2002)
J Clin Oncol
, vol.20
, pp. 2045-2052
-
-
Eton, O.1
Legha, S.S.2
Bedikian, A.Y.3
-
11
-
-
1642275644
-
A prospective randomized phase III trial of concurrent biochemotherapy (BCT) with cisplatin, vinblas- tine, dacarbazine (CVD), IL-2 and interferon alpha-2b (IFN) versus CVD alone in patients with metastatic melanoma (E3695): An ECOG-coordinated intergroup trial (abstr 2847)
-
Atkins MB, Lee S, Flaherty LE, Sosman JA, Sondak VK, Kirkwood JM. A prospective randomized phase III trial of concurrent biochemotherapy (BCT) with cisplatin, vinblas- tine, dacarbazine (CVD), IL-2 and interferon alpha-2b (IFN) versus CVD alone in patients with metastatic melanoma (E3695): An ECOG-coordinated intergroup trial (abstr 2847). Proc Am Soc Clin Oncol. 2003;22:7081.
-
(2003)
Proc Am Soc Clin Oncol
, vol.22
, pp. 7081
-
-
Atkins, M.B.1
Lee, S.2
Flaherty, L.E.3
Sosman, J.A.4
Sondak, V.K.5
Kirkwood, J.M.6
-
12
-
-
0030694235
-
IGIF does not drive Th1 development but synergizes with IL-12 for interferon-g production and activates IRAK and NFkB
-
Robinson D, Shibuya K, Mui A, et al. IGIF does not drive Th1 development but synergizes with IL-12 for interferon-g production and activates IRAK and NFkB. Immunity. 1997;7:571-581.
-
(1997)
Immunity
, vol.7
, pp. 571-581
-
-
Robinson, D.1
Shibuya, K.2
Mui, A.3
-
13
-
-
0032193770
-
IL-12 upregulates IL-18 receptor expression on T cells, Th1 cells, and B cells: Synergism with IL-18 for IFN-g production
-
Yoshimoto T, Takeda K, Tanaka T, et al. IL-12 upregulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN-g production. J Immunol. 1998;161:3400-3407.
-
(1998)
J Immunol
, vol.161
, pp. 3400-3407
-
-
Yoshimoto, T.1
Takeda, K.2
Tanaka, T.3
-
14
-
-
2642674449
-
IFN-gamma-inducing factor/IL-18 administration mediates IFN-gamma- and IL- 12-independent antitumor effects
-
Osaki T, Peron JM, Cai Q, et al. IFN-gamma-inducing factor/IL-18 administration mediates IFN-gamma- and IL- 12-independent antitumor effects. J Immunol. 1998;160:1742-1749.
-
(1998)
J Immunol
, vol.160
, pp. 1742-1749
-
-
Osaki, T.1
Peron, J.M.2
Cai, Q.3
-
15
-
-
0032521153
-
Interleukin- 12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis
-
Coughlin CM, Salhany KE, Wysocka M, et al. Interleukin- 12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. J Clin Invest. 1998;101:1441-1452.
-
(1998)
J Clin Invest
, vol.101
, pp. 1441-1452
-
-
Coughlin, C.M.1
Salhany, K.E.2
Wysocka, M.3
-
16
-
-
0034105411
-
Antitumor effects on mouse melanoma elicited by local secretion of interleukin-12 and their enhancement by treatment with interleukin-18
-
Nagai H, Hara I, Horikawa T, et al. Antitumor effects on mouse melanoma elicited by local secretion of interleukin-12 and their enhancement by treatment with interleukin-18. Cancer Invest. 2000;18:206-213.
-
(2000)
Cancer Invest
, vol.18
, pp. 206-213
-
-
Nagai, H.1
Hara, I.2
Horikawa, T.3
-
17
-
-
0033994272
-
Interleukin-18 in combination with IL-2 enhances natural killer cell activity without inducing large amounts of IFN-gamma in vivo
-
Arai N, Akamatsu S, Arai S, et al. Interleukin-18 in combination with IL-2 enhances natural killer cell activity without inducing large amounts of IFN-gamma in vivo. J Interferon Cytokine Res. 2000;20:217-224.
-
(2000)
J Interferon Cytokine Res
, vol.20
, pp. 217-224
-
-
Arai, N.1
Akamatsu, S.2
Arai, S.3
-
18
-
-
0032786495
-
Interleukin-18 acts as an angiogenesis and tumor suppressor
-
Cao R, Farnebo J, Kurimoto M, Cao Y. Interleukin-18 acts as an angiogenesis and tumor suppressor. FASEB J. 1999; 13:2195-2202.
-
(1999)
FASEB J
, vol.13
, pp. 2195-2202
-
-
Cao, R.1
Farnebo, J.2
Kurimoto, M.3
Cao, Y.4
-
19
-
-
0012122533
-
Interleukin-18: Biological properties and clinical implications
-
Lebel-Binay S, Berger A, Zinzindohoue F, et al. Interleukin-18: biological properties and clinical implications. Eur Cytokine Netw. 2000;11:15-26.
-
(2000)
Eur Cytokine Netw
, vol.11
, pp. 15-26
-
-
Lebel-Binay, S.1
Berger, A.2
Zinzindohoue, F.3
-
20
-
-
0031749136
-
Overview of interleukin-18: More than an interferon-gamma inducing factor
-
Dinarello CA, Novick D, Puren AJ, et al. Overview of interleukin-18: more than an interferon-gamma inducing factor. J Leukoc Biol. 1998;63:658-664.
-
(1998)
J Leukoc Biol
, vol.63
, pp. 658-664
-
-
Dinarello, C.A.1
Novick, D.2
Puren, A.J.3
-
21
-
-
0032747002
-
Interleukin-18
-
Dinarello CA. Interleukin-18. Methods. 1999;19:121-132.
-
(1999)
Methods
, vol.19
, pp. 121-132
-
-
Dinarello, C.A.1
-
22
-
-
0035117174
-
Interleukin-18 (IL-18) synergizes with IL-2 to enhance cytotoxicity, interferon-gamma production, and expansion of natural killer cells
-
Son YI, Dallal RM, Mailliard RB, Egawa S, Jonak ZL, Lotze MT. Interleukin-18 (IL-18) synergizes with IL-2 to enhance cytotoxicity, interferon-gamma production, and expansion of natural killer cells. Cancer Res. 2001;61:884-888.
-
(2001)
Cancer Res
, vol.61
, pp. 884-888
-
-
Son, Y.I.1
Dallal, R.M.2
Mailliard, R.B.3
Egawa, S.4
Jonak, Z.L.5
Lotze, M.T.6
-
23
-
-
0033561762
-
Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: Implications for the innate immune response
-
Fehniger TA, Shah MH, Turner MJ, et al. Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response. J Immunol. 1999;162:4511-4520.
-
(1999)
J Immunol
, vol.162
, pp. 4511-4520
-
-
Fehniger, T.A.1
Shah, M.H.2
Turner, M.J.3
-
24
-
-
0033565876
-
Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand-and perforin-induced tumor apoptosis, respectively
-
Hashimoto W, Osaki T, Okamura H, et al. Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand-and perforin-induced tumor apoptosis, respectively. J Immunol. 1999;163:583-589.
-
(1999)
J Immunol
, vol.163
, pp. 583-589
-
-
Hashimoto, W.1
Osaki, T.2
Okamura, H.3
-
25
-
-
0032700570
-
Synergistic proliferation and activation of natural killer cells by interleukin 12 and interleukin 18
-
Lauwerys BR, Renauld JC, Houssiau FA. Synergistic proliferation and activation of natural killer cells by interleukin 12 and interleukin 18. Cytokine. 1999;11:822-830.
-
(1999)
Cytokine
, vol.11
, pp. 822-830
-
-
Lauwerys, B.R.1
Renauld, J.C.2
Houssiau, F.A.3
-
26
-
-
27744482893
-
Tolerability and anti-tumor activity of recombinant human IL-18 (rhIL-18) administered as five daily intravenous infusions in patients with solid tumors
-
Robertson MJ, Mier J, Logan T, et al. Tolerability and anti-tumor activity of recombinant human IL-18 (rhIL-18) administered as five daily intravenous infusions in patients with solid tumors. Proc Am Soc Clin Oncol. 2004;22:2553.
-
(2004)
Proc Am Soc Clin Oncol
, vol.22
, pp. 2553
-
-
Robertson, M.J.1
Mier, J.2
Logan, T.3
-
27
-
-
33645536884
-
Phase I study of recombinant human IL-18 (rhIL-18) administered as 5 daily intravenous infusions every 28 days in patients with solid tumors
-
Robertson MJ, Kirkwood M, Logan T, et al. Phase I study of recombinant human IL-18 (rhIL-18) administered as 5 daily intravenous infusions every 28 days in patients with solid tumors J Clin Oncol. 2005;23:2513.
-
(2005)
J Clin Oncol
, vol.23
, pp. 2513
-
-
Robertson, M.J.1
Kirkwood, M.2
Logan, T.3
-
28
-
-
0034594628
-
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
-
Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
-
(2000)
J Natl Cancer Inst
, vol.92
, pp. 205-216
-
-
Therasse, P.1
Arbuck, S.G.2
Eisenhauer, E.A.3
-
29
-
-
50349092728
-
A dose- escalation study of recombinant human Interleukin-18 using two different schedules of administration in patients with cancer
-
Robertson MJ, Kirkwood JM, Logan TF, et al. A dose- escalation study of recombinant human Interleukin-18 using two different schedules of administration in patients with cancer. Clin Cancer Res. 2008;14:3462-3469.
-
(2008)
Clin Cancer Res
, vol.14
, pp. 3462-3469
-
-
Robertson, M.J.1
Kirkwood, J.M.2
Logan, T.F.3
-
30
-
-
0035154256
-
Clinical trial designs for cytostatic agents: Are new approaches needed?
-
Korn EL, Arbuck SG, Pluda JM, Simon R, Kaplan RS, Christian MC. Clinical trial designs for cytostatic agents: are new approaches needed? J Clin Oncol. 2001;19:265-272.
-
(2001)
J Clin Oncol
, vol.19
, pp. 265-272
-
-
Korn, E.L.1
Arbuck, S.G.2
Pluda, J.M.3
Simon, R.4
Kaplan, R.S.5
Christian, M.C.6
-
31
-
-
39149104690
-
Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma: Determining progression-free and overall survival benchmarks for future phase II Trials
-
Korn E, Liu P-Y, Lee S, et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma: determining progression-free and overall survival benchmarks for future phase II Trials. J Clin Oncol. 2008;26:527-534.
-
(2008)
J Clin Oncol
, vol.26
, pp. 527-534
-
-
Korn, E.1
Liu, P.-Y.2
Lee, S.3
-
32
-
-
33751266583
-
Combined stimulation with interleukin-18 and CpG induces murine natural killer dendritic cells to produce IFN-gamma and inhibit tumor growth
-
Chaudhry UI, Kingham TP, Plitas G, Katz SC, Raab JR, DeMatteo RP. Combined stimulation with interleukin-18 and CpG induces murine natural killer dendritic cells to produce IFN-gamma and inhibit tumor growth. Cancer Res. 2006;66:10497-10504.
-
(2006)
Cancer Res
, vol.66
, pp. 10497-10504
-
-
Chaudhry, U.I.1
Kingham, T.P.2
Plitas, G.3
Katz, S.C.4
Raab, J.R.5
DeMatteo, R.P.6
-
33
-
-
36949017263
-
Enhanced suppression of pulmonary metastasis of malignant melanoma cells by combined administration of alpha-galactosylceramide and interleukin-18
-
Nishio S, Yamada N, Ohyama H, et al. Enhanced suppression of pulmonary metastasis of malignant melanoma cells by combined administration of alpha-galactosylceramide and interleukin-18. Cancer Sci. 2007;99:113-120.
-
(2007)
Cancer Sci
, vol.99
, pp. 113-120
-
-
Nishio, S.1
Yamada, N.2
Ohyama, H.3
-
34
-
-
36749056333
-
A mycoplasma peptide elicits heteroclitic CD4+ T cell responses against tumor antigen MAGE-A6
-
Vujanovic L, Mandic M, Olson WC, Kirkwood JM, Storkus WJ. A mycoplasma peptide elicits heteroclitic CD4+ T cell responses against tumor antigen MAGE-A6. Clin Cancer Res. 2007;13:6796-6806.
-
(2007)
Clin Cancer Res
, vol.13
, pp. 6796-6806
-
-
Vujanovic, L.1
Mandic, M.2
Olson, W.C.3
Kirkwood, J.M.4
Storkus, W.J.5
|